An overview of analgesics - anticonvulsants, antidepressants, and other medications (Part 3)
Pain is classified by various descriptions. Chronic pain has been described as being neuropathic (due to nervous system lesions), nociceptive (due to tissue damage), or mixed (a combination of neuropathic and nociceptive). The addition of the term nociplastic pain is used to describe patients who ex...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AOSIS
2019-07-01
|
| Series: | South African Family Practice |
| Subjects: | |
| Online Access: | https://safpj.co.za/index.php/safpj/article/view/4972 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849234210851651584 |
|---|---|
| author | R. van Rensburg H. Reuter |
| author_facet | R. van Rensburg H. Reuter |
| author_sort | R. van Rensburg |
| collection | DOAJ |
| description | Pain is classified by various descriptions. Chronic pain has been described as being neuropathic (due to nervous system lesions), nociceptive (due to tissue damage), or mixed (a combination of neuropathic and nociceptive). The addition of the term nociplastic pain is used to describe patients who experience chronic pain without tissue damage or nervous system lesions. Chronic pain is often difficult to manage, particularly neuropathic pain. Evidence-based pharmacological treatment options include anticonvulsants and antidepressants. The choice of medication will depend on various factors, including patient profile, type of pain, and associated conditions. Medications with the best evidence of efficacy for first-line use in neuropathic pain are the gabapentinoids, carbamazepine, the tricyclic antidepressants, and the serotonin-noradrenaline reuptake inhibitors duloxetine and venlafaxine. The cannabinoids and ketamine are being actively investigated for use in chronic pain. Currently the cannabinoids’ potential benefit is outweighed by the adverse effects, and recommendations for the use of ketamine is limited by its parenteral route of administration and low evidence of efficacy in chronic pain. |
| format | Article |
| id | doaj-art-012f757ae2f54d058b7994e240aba83c |
| institution | Kabale University |
| issn | 2078-6190 2078-6204 |
| language | English |
| publishDate | 2019-07-01 |
| publisher | AOSIS |
| record_format | Article |
| series | South African Family Practice |
| spelling | doaj-art-012f757ae2f54d058b7994e240aba83c2025-08-20T04:03:13ZengAOSISSouth African Family Practice2078-61902078-62042019-07-01613596310.4102/safp.v61i3.49723948An overview of analgesics - anticonvulsants, antidepressants, and other medications (Part 3)R. van Rensburg0H. Reuter1Stellenbosch UniversityStellenbosch UniversityPain is classified by various descriptions. Chronic pain has been described as being neuropathic (due to nervous system lesions), nociceptive (due to tissue damage), or mixed (a combination of neuropathic and nociceptive). The addition of the term nociplastic pain is used to describe patients who experience chronic pain without tissue damage or nervous system lesions. Chronic pain is often difficult to manage, particularly neuropathic pain. Evidence-based pharmacological treatment options include anticonvulsants and antidepressants. The choice of medication will depend on various factors, including patient profile, type of pain, and associated conditions. Medications with the best evidence of efficacy for first-line use in neuropathic pain are the gabapentinoids, carbamazepine, the tricyclic antidepressants, and the serotonin-noradrenaline reuptake inhibitors duloxetine and venlafaxine. The cannabinoids and ketamine are being actively investigated for use in chronic pain. Currently the cannabinoids’ potential benefit is outweighed by the adverse effects, and recommendations for the use of ketamine is limited by its parenteral route of administration and low evidence of efficacy in chronic pain.https://safpj.co.za/index.php/safpj/article/view/4972neuropathic painanticonvulsantsantidepressantsevidence-basedcannabinoids |
| spellingShingle | R. van Rensburg H. Reuter An overview of analgesics - anticonvulsants, antidepressants, and other medications (Part 3) South African Family Practice neuropathic pain anticonvulsants antidepressants evidence-based cannabinoids |
| title | An overview of analgesics - anticonvulsants, antidepressants, and other medications (Part 3) |
| title_full | An overview of analgesics - anticonvulsants, antidepressants, and other medications (Part 3) |
| title_fullStr | An overview of analgesics - anticonvulsants, antidepressants, and other medications (Part 3) |
| title_full_unstemmed | An overview of analgesics - anticonvulsants, antidepressants, and other medications (Part 3) |
| title_short | An overview of analgesics - anticonvulsants, antidepressants, and other medications (Part 3) |
| title_sort | overview of analgesics anticonvulsants antidepressants and other medications part 3 |
| topic | neuropathic pain anticonvulsants antidepressants evidence-based cannabinoids |
| url | https://safpj.co.za/index.php/safpj/article/view/4972 |
| work_keys_str_mv | AT rvanrensburg anoverviewofanalgesicsanticonvulsantsantidepressantsandothermedicationspart3 AT hreuter anoverviewofanalgesicsanticonvulsantsantidepressantsandothermedicationspart3 AT rvanrensburg overviewofanalgesicsanticonvulsantsantidepressantsandothermedicationspart3 AT hreuter overviewofanalgesicsanticonvulsantsantidepressantsandothermedicationspart3 |